News
TGTX
5.05
+1.20%
0.06
TG Therapeutics Announces Data Presentations From The ULTIMATE I & II Phase 3 Trials Of Ublituximab In Multiple Sclerosis To Be Presented At The 2022 Consortium Of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the schedule of data presentations, including one oral and two poster presentations, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating
Benzinga · 1d ago
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and two poster presentations, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating ublit...
GlobeNewswire · 1d ago
Peering Into TG Therapeutics's Recent Short Interest
TG Therapeutics's (NASDAQ:TGTX) short percent of float has fallen 8.05% since its last report. The company recently reported that it has 19.37 million shares sold short, which is 14.63% of all regular shares that are available for trading.
Benzinga · 6d ago
TG Therapeutics downgraded at BofA with a bearish view on blood cancer candidate
The commercial-stage biotech, TG Therapeutics (NASDAQ:TGTX) is trading lower for the third straight session on Friday after Bank of America downgraded the company citing the commercial setup of its investigational
Seekingalpha · 6d ago
TG Therapeutics' Shares Plummet After BofA Securities Initiates Coverage at Underperform
MT Newswires · 6d ago
What 4 Analyst Ratings Have To Say About TG Therapeutics
Over the past 3 months, 4 analysts have published their opinion on TG Therapeutics (NASDAQ:TGTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade ov...
Benzinga · 05/20 12:30
TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ETNEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Off...
GlobeNewswire · 05/20 11:30
BofA Securities Starts TG Therapeutics at Underperform With $5 Price Target
MT Newswires · 05/20 06:45
Is TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shareholder Ownership Skewed Towards Insiders?
If you want to know who really controls TG Therapeutics, Inc. ( NASDAQ:TGTX ), then you'll have to look at the makeup...
Simply Wall St. · 05/12 12:34
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.95% and 57.49%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 12:15
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Surpass Estimates
Zimmer (ZBH) delivered earnings and revenue surprises of 15% and 4.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/03 11:45
Will TG Therapeutics (TGTX) Report Negative Q1 Earnings? What You Should Know
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 05/02 19:00
TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference
Fireside chat scheduled for Thursday, April 28, 2022 at 12:30 PM ETNEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participat...
GlobeNewswire · 04/26 11:30
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.
Benzinga · 04/21 19:08
Expert Ratings for TG Therapeutics
TG Therapeutics (NASDAQ:TGTX) has observed the following analyst ratings within the last quarter:
Benzinga · 04/19 20:01
TG Therapeutics (TGTX) Withdraws FDA Submission, Stock Down
TG Therapeutics (TGTX) voluntarily withdraws regulatory application seeking approval for the combination regimen, ublituximab plus Ukoniq. It also withdraws Ukoniq from sale in approved indications.
Zacks · 04/19 15:02
B. Riley Lowers TG Therapeutics' PT to $23 from $35, Says Exit from Oncology 'Disappointing'; Keeps Buy Rating
MT Newswires · 04/19 08:11
Hot Stocks: CASA soars on VZ investment; SWX potential bidding war; TGTX, NKTR drop on drug setbacks
Stocks recorded fractional declines on Monday, bouncing around during the session as investors waited for signals from incoming earnings reports due out during the rest of the week.  Even with
Seekingalpha · 04/18 22:46
Despite Price Cut, HC Wainwright Keeps Buy Rating On TG Therapeutics - Read Why
Benzinga · 04/18 19:34
Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares Slide
U.S. stocks traded higher in volatile session, with the Dow Jones gaining around 60 points toward the end of trading on Monday.
Benzinga · 04/18 18:34
More
Webull provides a variety of real-time TGTX stock news. You can receive the latest news about Tg Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TGTX
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company that is focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The Company’s two programs in Phase III development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase I clinical development. The Company’s clinical programs are focused on Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), CLL, and MS. MZL comprises a group of indolent (slow-growing) mature B-cell non-Hodgkin lymphomas (NHLs). MZL consists of three different subtypes extranodal MZL of the mucosal-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZL), and splenic marginal zone lymphoma (SMZL).